- Home
- SNDL vs REPL Comparison
SNDL vs REPL Comparison
Compare SNDL & REPL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNDL
- REPL
- Stock Information
- Founded
- SNDL 2006
- REPL 2015
- Country
- SNDL Canada
- REPL United States
- Employees
- SNDL N/A
- REPL N/A
- Industry
- SNDL Pharmaceuticals and Biotechnology
- REPL Biotechnology: Pharmaceutical Preparations
- Sector
- SNDL Health Care
- REPL Health Care
- Exchange
- SNDL Nasdaq
- REPL Nasdaq
- Market Cap
- SNDL 510.3M
- REPL 690.7M
- IPO Year
- SNDL 2019
- REPL 2018
- Fundamental
- Price
- SNDL $2.01
- REPL $11.31
- Analyst Decision
- SNDL Buy
- REPL Strong Buy
- Analyst Count
- SNDL 1
- REPL 5
- Target Price
- SNDL $3.25
- REPL $24.00
- AVG Volume (30 Days)
- SNDL 1.5M
- REPL 905.0K
- Earning Date
- SNDL 11-11-2024
- REPL 11-05-2024
- Dividend Yield
- SNDL N/A
- REPL N/A
- EPS Growth
- SNDL N/A
- REPL N/A
- EPS
- SNDL N/A
- REPL N/A
- Revenue
- SNDL $666,293,063.00
- REPL N/A
- Revenue This Year
- SNDL $2.94
- REPL N/A
- Revenue Next Year
- SNDL $5.26
- REPL $511.76
- P/E Ratio
- SNDL N/A
- REPL N/A
- Revenue Growth
- SNDL 2.02
- REPL N/A
- 52 Week Low
- SNDL $1.30
- REPL $4.92
- 52 Week High
- SNDL $2.93
- REPL $15.33
- Technical
- Relative Strength Index (RSI)
- SNDL 50.05
- REPL 52.26
- Support Level
- SNDL $1.97
- REPL $9.94
- Resistance Level
- SNDL $2.02
- REPL $12.03
- Average True Range (ATR)
- SNDL 0.05
- REPL 0.78
- MACD
- SNDL 0.01
- REPL -0.08
- Stochastic Oscillator
- SNDL 50.00
- REPL 46.92
About SNDL SNDL Inc.
SNDL Inc is a private-sector liquor and cannabis retailer in Canada with retail banners that include Ace Liquor, Wine and Beyond, Liquor Depot, Value Buds, and Spiritleaf. The principal activities of the company are the retailing of wines, beers, and spirits. It comprised four reportable segments: liquor retail, cannabis retail, cannabis operations, and investments. Liquor retail includes the sale of wines, beers, and spirits through owned liquor stores. The company generates maximum revenue from liquor retail.
About REPL Replimune Group Inc.
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3.